CA
NZ
UK
AU
IND
US
…
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
LivaNova PLC is a global medical technology company that develops and sells devices and therapies primarily in cardiac surgery and neuromodulation, including vagus nerve stimulation therapies and circulatory support products. Long-term growth may be driven by demographic trends increasing demand for cardiac and neurological therapies, recurring revenues from consumables and implants, and expansion of neuromodulation indications, which could improve revenue visibility.
Principal risks include regulatory or clinical setbacks, reimbursement pressure, intense device competition, and execution or supply-chain disruptions that could hurt sales and margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -75.10M | -124.50M | -344.00M | -185.70M | -247.40M |
| Net income | -86.20M | -135.70M | -343.30M | -155.50M | -189.40M |
| Selling general administrative | 469.24M | 471.90M | 427.77M | 506.54M | 462.41M |
| Gross profit | 707.20M | 706.00M | 618.20M | 744.80M | 734.50M |
| Reconciled depreciation | 57.80M | 67.90M | 81.32M | 82.99M | 69.94M |
| Ebit | 52.70M | -0.90M | -42.80M | 48.00M | 86.30M |
| Ebitda | 110.50M | 67.00M | 38.50M | 131.00M | 156.20M |
| Depreciation and amortization | 57.80M | 67.90M | 81.30M | 83.00M | 69.90M |
| Non operating income net other | - | -59.95M | -0.13M | - | 11.69M |
| Operating income | 52.70M | -0.90M | -42.80M | 48.00M | -248.10M |
| Other operating expenses | 969.10M | 1036.20M | 977.20M | 1036.20M | 1020.70M |
| Interest expense | 48.30M | 49.70M | 40.70M | 14.30M | 9.00M |
| Tax provision | 11.05M | 11.20M | -0.70M | -30.15M | -69.63M |
| Interest income | 4.70M | 0.43M | 0.13M | 0.80M | 0.85M |
| Net interest income | -43.55M | -49.70M | -40.70M | -14.29M | -8.98M |
| Extraordinary items | - | - | - | 0.36M | -10.94M |
| Non recurring | - | - | 227.00M | - | 334.36M |
| Income tax expense | 11.10M | 11.20M | -0.70M | -30.20M | -69.60M |
| Total revenue | 1021.80M | 1035.40M | 934.20M | 1084.20M | 1107.00M |
| Total operating expenses | 654.50M | 706.80M | 661.20M | 696.80M | 648.20M |
| Cost of revenue | 314.60M | 329.40M | 316.00M | 339.40M | 372.50M |
| Total other income expense net | -127.80M | -123.60M | -301.20M | -233.70M | -324.70M |
| Discontinued operations | - | - | -1.50M | 0.36M | -10.94M |
| Net income from continuing ops | -86.25M | -135.80M | -343.25M | -155.54M | -178.46M |
| Net income applicable to common shares | -86.25M | -135.80M | -345.01M | -155.18M | -189.40M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2429.56M | 2294.80M | 2201.00M | 2411.40M | 2411.80M |
| Intangible assets | 261.18M | 368.60M | 399.70M | 437.60M | 607.50M |
| Other current assets | 47.33M | 25.00M | 35.80M | 24.80M | 28.50M |
| Total liab | 1151.93M | 1087.20M | 906.40M | 1292.60M | 1028.10M |
| Total stockholder equity | 1277.63M | 1207.60M | 1294.60M | 1118.80M | 1383.70M |
| Deferred long term liab | - | - | - | 130.85M | - |
| Other current liab | 216.94M | 189.47M | 390.88M | 215.17M | 342.57M |
| Common stock | 82.53M | 82.42M | 82.30M | 76.30M | 76.26M |
| Capital stock | 82.53M | 82.42M | 82.30M | 76.30M | 76.26M |
| Retained earnings | -966.48M | -984.03M | -897.78M | -752.40M | -406.75M |
| Other liab | - | 242.14M | 163.70M | 299.00M | 209.11M |
| Good will | 782.94M | 768.80M | 899.50M | 922.30M | 915.80M |
| Other assets | - | 72.01M | 15.30M | 0.20M | -0.10M |
| Cash | 577.87M | 214.20M | 208.00M | 252.80M | 61.10M |
| Total current liabilities | 334.98M | 297.40M | 697.00M | 309.10M | 512.60M |
| Current deferred revenue | 10.72M | 10.23M | 8.42M | 6.93M | 6.73M |
| Net debt | 62.53M | 356.80M | 67.40M | 445.00M | 322.60M |
| Short term debt | 26.47M | 23.40M | 229.70M | 13.30M | 77.40M |
| Short long term debt | 18.11M | 23.43M | 229.70M | 13.30M | 77.40M |
| Short long term debt total | 640.40M | 571.00M | 275.40M | 697.80M | 383.70M |
| Other stockholder equity | 2189.46M | 2157.32M | 2117.27M | 1767.09M | 1733.59M |
| Property plant equipment | - | 183.02M | 190.70M | 163.81M | 235.73M |
| Total current assets | 988.16M | 886.10M | 679.20M | 719.40M | 549.40M |
| Long term investments | 22.84M | 16.27M | 16.60M | 103.40M | 27.26M |
| Net tangible assets | - | 70.28M | -4.60M | -241.12M | -139.62M |
| Short term investments | - | -0.03M | -0.00M | 31.09M | - |
| Net receivables | 215.07M | 183.10M | 185.40M | 184.40M | 257.80M |
| Long term debt | 568.54M | 518.07M | 9.80M | 642.30M | 260.33M |
| Inventory | 147.89M | 129.40M | 105.80M | 126.70M | 164.20M |
| Accounts payable | 80.84M | 74.30M | 68.00M | 73.70M | 85.90M |
| Accumulated other comprehensive income | -27.88M | -48.12M | -7.18M | 27.81M | -19.39M |
| Common stock total equity | - | - | 82.30M | 76.30M | 76.26M |
| Retained earnings total equity | - | - | -897.78M | -752.40M | - |
| Treasury stock | - | - | -0.65M | -1.03M | -1.26M |
| Non currrent assets other | 12.06M | 70.60M | 13.10M | 83.50M | 7.40M |
| Non current assets total | 1441.40M | 1408.70M | 1521.80M | 1691.80M | 1862.50M |
| Capital lease obligations | 53.75M | 38.93M | 35.90M | 42.20M | 57.14M |
| Long term debt total | - | - | - | 642.30M | 260.33M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -38.41M | 19.40M | -5.88M | -41.29M | -3.77M |
| Change to liabilities | -3.51M | 13.00M | 2.67M | -38.58M | 13.68M |
| Total cashflows from investing activities | -38.41M | 36.90M | -41.84M | -41.29M | -120.56M |
| Net borrowings | 284.01M | -487.90M | 339.35M | 171.76M | 59.74M |
| Total cash from financing activities | 280.10M | -181.50M | 310.80M | 146.60M | -42.30M |
| Change to operating activities | 0.93M | 27.40M | -173.90M | -125.77M | 287.58M |
| Net income | -86.20M | -135.80M | -345.00M | -155.20M | -189.40M |
| Change in cash | 307.60M | -44.80M | 191.70M | 13.90M | -46.40M |
| Begin period cash flow | 208.00M | 252.80M | 61.10M | 47.20M | 93.60M |
| End period cash flow | 515.60M | 208.00M | 252.80M | 61.10M | 47.20M |
| Total cash from operating activities | 69.90M | 102.50M | -79.40M | -91.10M | 120.50M |
| Issuance of capital stock | 0.00M | 322.56M | - | - | - |
| Depreciation | 57.80M | 67.90M | 81.30M | 83.00M | 69.90M |
| Other cashflows from investing activities | -0.09M | 1.80M | -0.94M | -1.32M | -78.79M |
| Change to inventory | -25.70M | 4.50M | 1.40M | -10.60M | -10.60M |
| Change to account receivables | -4.80M | -15.70M | 58.80M | -5.30M | 21.20M |
| Sale purchase of stock | -8.70M | -12.90M | -5.60M | -7.10M | -61.60M |
| Other cashflows from financing activities | 512.30M | -3.30M | 844.20M | 179.10M | 333.80M |
| Change to netincome | 108.73M | 124.40M | 261.35M | 167.56M | -80.56M |
| Capital expenditures | 26.50M | 25.50M | 35.00M | 28.00M | 38.00M |
| Change receivables | - | -15.74M | 58.80M | - | 21.18M |
| Cash flows other operating | - | 63.88M | -137.85M | - | 282.93M |
| Exchange rate changes | - | - | - | - | -4.00M |
| Cash and cash equivalents changes | - | -42.03M | 189.49M | - | -46.41M |
| Change in working capital | -31.70M | 26.00M | -111.00M | -58.20M | 4.80M |
| Stock based compensation | 44.80M | 40.60M | 35.10M | 32.60M | 26.90M |
| Other non cash items | 83.80M | 100.90M | 222.90M | 33.00M | 303.40M |
| Free cash flow | 43.40M | 77.00M | -114.40M | -119.10M | 82.50M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LIVN LivaNova PLC |
-2.28 2.81% |
78.97 | - | 27.17 | 2.48 | 2.24 | 2.80 | 84.04 |
| ABT Abbott Laboratories |
1.63 1.56% |
106.20 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.57 0.59% |
96.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.89 6.38% |
291.86 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Damien McDonald | CEO & Director | 1965 |
| Mr. Alex Shvartsburg | Chief Financial Officer | 1971 |
| Ms. Trui Hebbelinck | Chief HR Officer | 1972 |
| Ms. Keyna Pidcock Skeffington | Sr. VP, Special Advisor & Exec. Officer | 1963 |
| Mr. Marco Dolci | Pres of Cardiopulmonary Bus. Unit | 1962 |
| Lindsey Little | Sr. Director of Investor Relations | NA |
| Mr. Michael Hutchinson | Sr. VP, Chief Legal Officer and Company Sec. | NA |
| Deanna Wilke | VP of Corp. Communications | NA |
| Mr. Matthew Joseph Dodds III | Sr. VP of Corp. Devel. | NA |
| Dr. Bryan D. Olin Ph.D. | Sr. VP & Head of Product Devel. - Neuromodulation | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-2.01%
Communication Services
-0.38%
Consumer Cyclical
-0.21%
Consumer Defensive
+0.35%
Energy
-0.11%
Financial Services
-0.91%
Financials
+2.38%
Healthcare
-1.52%
Industrials
-1.04%
Real Estate
-0.24%
Technology
-3.19%
Utilities
-0.34%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...